- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CT medium circulates in blood pool
Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion
Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion and blood pool agent. Preclinical studies indicate that the proprietary agent, called PH-50, has potential in coronary, cardiac, great vessel, and renal arterial CT. Through luminaries at Stanford University, the New Hope, PA, company also hopes to explore the use of this agent as a means for imaging soft noncalcified plaques in coronary arteries, where its presence is a marker of likelihood to rupture and cause sudden death.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
